Misys has launched Summit Invest, a buy-side derivatives system, designed to enable trading, risk management, trade processing and OTC lifecycle management in a tailored buy-side environment. It includes new features to try and ensure organisations handle the complexity, risk and regulatory reporting of these complex products.

The solution is reportedly being deployed this month by a major UK-based asset manager. The platform consolidates positions across asset classes and includes pricing, risk analysis, collateral management and lifecycle management of OTCs. It combines this proven OTC functionality with new portfolio functionality, valuation techniques and reporting.